Getting The Deal Through logo
Getting The Deal Through


Russian AIDS drug collusion probe spreads to Bristol-Myers

Pharma - News – 16 October 2018

Russia’s Federal Antimonopoly Service has expanded its investigation into potential collusion in the pharmaceutical market by raiding the offices of Bristol-Myers Squibb.


EU Parliament backs new health technology assessment legislation

Pharma - News – 10 October 2018

The European Parliament has approved a report from the EU’s Environment, Public Health and Food Safety Committee (ENVI) calling for the introduction of new health technology assessment (HTA) rules across the bloc.


No scope for appeal in UCB/Chugai patent dispute, English judge rules

Pharma - News – 10 October 2018

An English judge has largely dismissed Belgian pharmaceutical company UCB’s draft grounds for appeal after it lost a patent litigation against Japan’s Chugai Pharmaceutical in August.


AmerisourceBergen pays DoJ US$625m over repackaging claims

Pharma - News – 10 October 2018

US drug wholesaler AmerisourceBergen and four of its subsidiaries have struck a deal with the Department of Justice to settle claims they illegally pooled and repackaged cancer drugs.  


Court clears Fresenius to end Akorn acquisition

Pharma - News – 10 October 2018

A US judge has allowed Fresenius to scrap its planned $4.75 billion takeover of generic drugmaker Akorn, finding that the German healthcare company didn’t breach its merger agreement by pulling out of the deal after the target made false representations about the state of its data.


EU court throws out orphan drugmaker’s challenge to EMA disclosure

Pharma - News – 02 October 2018

The General Court of the European Union has dismissed an Anglo-American orphan drug company’s bid to block the European Medicines Agency from releasing a clinical study report for one of its treatments, finding the information wasn’t protected by EU rules on access to documents.






Follow Getting the Deal Through for the latest updates on law and regulation worldwide

Follow us on LinkedIn